Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 baxdrostat plus dapagliflozin versus dapagliflozin alone in chronic kidney disease with hypertension
MOH_2024-04-09_013355Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and hypertension (HTN) comparing Baxdrostat + dapagliflozin with Dapagliflozin + matched placebo (2 arms). Planned start Feb 2024; status: not yet recruiting.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on MOH_2024-04-09_013355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-09_013355.